Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 833

    1.

    Plasmodium vivax: who cares?

    Galinski MR, Barnwell JW.

    Malar J. 2008 Dec 11;7 Suppl 1:S9. Review.

    PMID:
    19091043
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    An update on the search for a Plasmodium vivax vaccine.

    Herrera S, Corradin G, Arévalo-Herrera M.

    Trends Parasitol. 2007 Mar;23(3):122-8. Epub 2007 Jan 29. Review.

    PMID:
    17258937
    [PubMed - indexed for MEDLINE]
    3.

    Plasmodium vivax malaria vaccine development.

    Arévalo-Herrera M, Herrera S.

    Mol Immunol. 2001 Dec;38(6):443-55. Review.

    PMID:
    11741694
    [PubMed - indexed for MEDLINE]
    4.

    Vaccination for vivax malaria: targeting the invaders.

    Polley SD, McRobert L, Sutherland CJ.

    Trends Parasitol. 2004 Mar;20(3):99-102. Review.

    PMID:
    16676415
    [PubMed - indexed for MEDLINE]
    5.

    Platform for Plasmodium vivax vaccine discovery and development.

    Valencia SH, Rodríguez DC, Acero DL, Ocampo V, Arévalo-Herrera M.

    Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:179-92. Review.

    PMID:
    21881773
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.

    Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA.

    Lancet Infect Dis. 2009 Sep;9(9):555-66. Review.

    PMID:
    19695492
    [PubMed - indexed for MEDLINE]
    7.

    Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response.

    Bueno LL, Fujiwara RT, Soares IS, Braga EM.

    Vaccine. 2008 Feb 26;26(9):1204-13. Epub 2008 Jan 14.

    PMID:
    18242795
    [PubMed - indexed for MEDLINE]
    8.

    Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.

    Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S.

    Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):16-24.

    PMID:
    16291762
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

    Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

    Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

    PMID:
    17544179
    [PubMed - indexed for MEDLINE]
    10.

    Towards a vaccine against Plasmodium vivax malaria.

    Beeson JG, Crabb BS.

    PLoS Med. 2007 Dec;4(12):e350. No abstract available.

    PMID:
    18092888
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria.

    Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K.

    Infect Immun. 1998 Apr;66(4):1500-6.

    PMID:
    9529073
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Current status of Plasmodium vivax vaccine.

    Arévalo-Herrera M, Chitnis C, Herrera S.

    Hum Vaccin. 2010 Jan;6(1):124-32. Epub 2010 Jan 26. Review.

    PMID:
    20009526
    [PubMed - indexed for MEDLINE]
    13.

    Overview: immunology of malaria and progress in malaria vaccine development.

    Tharavanij S.

    Southeast Asian J Trop Med Public Health. 1992 Sep;23 Suppl 4:71-87. Review. No abstract available.

    PMID:
    1364871
    [PubMed - indexed for MEDLINE]
    14.

    Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

    King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

    Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. Epub 2008 Jun 3.

    PMID:
    18523022
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Proteomic approaches to studying drug targets and resistance in Plasmodium.

    Cooper RA, Carucci DJ.

    Curr Drug Targets Infect Disord. 2004 Mar;4(1):41-51. Review.

    PMID:
    15032633
    [PubMed - indexed for MEDLINE]
    16.

    Vaccines against malaria: perspectives from Papua New Guinea.

    Mueller I, Genton B, Betuela I, Alpers MP.

    Hum Vaccin. 2010 Jan;6(1):17-20. Epub 2010 Jan 15. Review.

    PMID:
    20173407
    [PubMed - indexed for MEDLINE]
    17.

    Priorities in research and development of vaccines against Plasmodium vivax malaria.

    Brown GV, Moorthy VS, Reed Z, Mendis K, Arévalo-Herrera M, Alonso P; WHO MALVAC committee.

    Vaccine. 2009 Dec 9;27(52):7228-35. Epub 2009 Sep 15.

    PMID:
    19761835
    [PubMed - indexed for MEDLINE]
    18.

    Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.

    Collins WE, Kaslow DC, Sullivan JS, Morris CL, Galland GG, Yang C, Saekhou AM, Xiao L, Lal AA.

    Am J Trop Med Hyg. 1999 Mar;60(3):350-6.

    PMID:
    10466960
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Rapid immunochromatography-based detection of mixed-species malaria infection in Pakistan.

    Beg MA, Ali SS, Haqqee R, Khan MA, Qasim Z, Hussain R, Smego RA Jr.

    Southeast Asian J Trop Med Public Health. 2005 May;36(3):562-4.

    PMID:
    16124417
    [PubMed - indexed for MEDLINE]
    20.

    A highly infective Plasmodium vivax strain adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development.

    Pico de Coaña Y, Rodríguez J, Guerrero E, Barrero C, Rodríguez R, Mendoza M, Patarroyo MA.

    Vaccine. 2003 Sep 8;21(25-26):3930-7.

    PMID:
    12922128
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk